Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated August 10, 2017, serves as a report of a foreign private issuer for Aurinia Pharmaceuticals Inc. The filing incorporates by reference the Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the second quarter ended June 30, 2017. The document is incorporated into the company's Registration Statement on Form F-10 (File No. 333-206994).
Key Financial Metrics
The provided text is a cover sheet and exhibit index; it does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the incorporated exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. Such analysis is contained within the MD&A (Exhibit 99.2) referenced in this report.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in this cover document. Investors must refer to the incorporated MD&A (Exhibit 99.2) for these disclosures.
Investor Verification Checklist
- Verify the specific financial results for the quarter ended June 30, 2017, by reviewing Exhibit 99.1 (Interim Condensed Consolidated Financial Statements).
- Review Exhibit 99.2 (MD&A) for management's discussion of operational performance, liquidity, and capital resources.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-206994) to which this report is incorporated.
- Check the certifications provided by the Chief Executive Officer and Chief Financial Officer (Exhibits 99.3 and 99.4) for any disclosures regarding internal controls or fraud.